Skip to main content

GIP/GLP-1 RA Beneficial for Patients With Opioid, Alcohol Use Disorder

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 25, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Oct. 25, 2024 -- For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 RA) are associated with lower rates of opioid overdose and alcohol intoxication, according to a study published online Oct. 16 in Addiction.

Fares Qeadan, Ph.D., from the Parkinson School of Health Sciences and Public Health at Loyola University Chicago, and colleagues evaluated the strength of the GIP/GLP-1 RA and substance use-outcome association among patients with comorbid type 2 diabetes and obesity in a retrospective cohort study. The study included 503,747 patients with a history of OUD and 817,309 patients with a history of AUD.

The researchers found that significantly lower rates of opioid overdose and alcohol intoxication were reported in patients with GIP/GLP-1 RA prescriptions compared with those without such prescriptions (adjusted incidence rate ratios, 0.60 and 0.50, respectively). Among patients with OUD and AUD, the rate of incident opioid overdose and alcohol intoxication remained similarly protective for those prescribed GIP/GLP-1 RA when stratified by comorbid conditions.

"This study not only contributes to the evolving landscape of substance use therapy but also opens avenues for more comprehensive and effective treatment strategies for those affected by OUD and AUD," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Semaglutide May Reduce Craving in Alcohol Use Disorder

FRIDAY, Feb. 28, 2025 -- Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in...

2017 to 2022 Saw Rise in ED Orders for Buprenorphine for Opioid Use Disorder

THURSDAY, Feb. 27, 2025 -- Emergency clinicians in California increased prescription of buprenorphine for opioid use disorder (OUD) from 2017 to 2022, according to a study...

2022 to 2023 Saw Decrease in Rate of Drug Overdose Deaths in United States

THURSDAY, Feb. 20, 2025 -- From 2022 to 2023, there was a decrease in the age-adjusted rate of drug overdose death in the United States, according to a report published in the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.